Korro Bio, Inc.
KRRO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001703647
In the last 90 days, Korro Bio, Inc. insiders filed 1 open-market purchase and 6 sales; 106 institutions reported holding it in 13F filings for Q2 2026, worth $190.1M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $186.8M
- Insider buysLast 90 days, $884.8K in total
- 1
- Insider sellsLast 90 days, $2.16M in total
- 6
- 13F holdersQ2 2026, +9 vs. previous quarter
- 106
- 13F valueReported value at the end of Q2 2026
- $190.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $6.39M
- +181.5% year over year
- Net income, FY2025
- -$117.3M
- No comparable prior period
- Free cash flow, FY2025
- -$79.1M
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- −100.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $117.3M (1834.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.75M
- Shares sold short
- Change
- +16.3K
- +0.9% vs. previous
- Days to cover
- 8.18
- At average daily volume
Superinvestors holding KRRO, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding KRRO at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Korro Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 13, 2026 (view filing)5:13 PM ET | Nov 11-12 | 2 days | Formela Jean FrancoisDirector | SSale | −66.6K | $14.61 | −$973.6K | −35.5%121.2K after | 6 lots10b5-1 |
| Oct 26, 2026 (view filing)6:37 PM ET | Oct 22-26 | 4 days | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.001 par value per share | +79.8K | $11.09 | +$884.8K | +5.2%1.62M after | 4 lots |
| Sep 15, 2026 (view filing)4:15 PM ET | Sep 11-14 | 4 days | Formela Jean FrancoisDirector | SSale | −48.7K | $14.09 | −$686.2K | −26.9%132.7K after | 4 lots10b5-1 |
| Sep 14, 2026 (view filing)4:05 PM ET | Sep 11 | 3 days | Dolan OliverSenior Vice President, Finance | SSale | −5 | $13.72 | −$68.58 | 0.0%16.2K after | 10b5-1 |
| Sep 10, 2026 (view filing)4:05 PM ET | Sep 8-9 | 2 days | Dolan OliverSenior Vice President, Finance | SSale | −7.35K | $13.51 | −$99.4K | −31.2%16.2K after | 2 lots10b5-1 |
| Aug 28, 2026 (view filing)4:30 PM ET | Aug 26 | 2 days | Formela Jean FrancoisDirector | SSale | −300 | $13.96 | −$4.19K | −0.2%141.0K after | 2 lots10b5-1 |
| Aug 21, 2026 (view filing)4:20 PM ET | Aug 19 | 2 days | Formela Jean FrancoisDirector | SSale | −28.5K | $14.00 | −$398.6K | −16.8%141.1K after | 2 lots10b5-1 |
| Aug 13, 2026 (view filing)5:04 PM ET | Aug 11 | 2 days | Formela Jean FrancoisDirector | SSale | −2.14K | $13.96 | −$29.9K | −1.4%145.9K after | 2 lots10b5-1 |
| Aug 13, 2026 (view filing)9:54 AM ET | Aug 6-10 | 7 daysLate | Nichols Weston and 1 other10% Owner | PPurchaseCommon stock, $0.001 par value per share | +6.68K | $11.79 | +$78.8K | +0.4%1.54M after | 2 lots |
| Aug 5, 2026 (view filing)4:05 PM ET | Aug 4 | 1 day | Aiyar RamPresident and CEO | SSale | −5.80K | $10.84 | −$62.9K | −7.8%69.0K after |
Top 10 13F holders, Q2 2026
See all 106 holdersThe largest institutional positions in Korro Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 1,538,296 | $20.3M | 2.34% | 00.0% | Unchanged |
| NEA Management Company, LLC | 1,297,893 | $17.1M | 1.08% | 00.0% | Unchanged |
| VR Adviser, LLC | 1,009,500 | $13.3M | 0.40% | 00.0% | Unchanged |
| Atlas Venture Life Science Advisors, LLC | 962,884 | $12.7M | 1.44% | −174,265−15.3% | Reduced |
| Balyasny Asset Management LLC | 951,783 | $12.5M | 0.02% | −88,271−8.5% | Reduced |
| BlackRock, Inc. | 817,621 | $10.8M | 0.00% | +357,615+77.7% | Added |
| Affinity Asset Advisors, LLC | 706,904 | $9.32M | 0.46% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 660,036 | $8.70M | 0.53% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 540,968 | $7.13M | 0.01% | +312,568+136.9% | Added |
| ADAR1 Capital Management, LLC | 540,054 | $7.12M | 0.33% | 00.0% | Unchanged |
Holders of 5% or more of KRRO
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Korro Bio, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 13G/A | 10.70%1.54M shares | +2.90 ppfrom 7.80% | Jan 5, 20262 filings | Apr 2, 2026 | SEC |
| Venrock Healthcare Capital Partners III, L.P. | 13G | 9.90%1.49M shares | New | Mar 17, 20261 filing | Mar 17, 2026 | SEC |
| New Enterprise Associates 17, L.P. | 13D/A | 9.90%1.46M shares | – | Nov 17, 20233 filings | Mar 12, 2026 | SEC |
| Adage Capital Management, L.P. | 13G | 6.79%1.00M shares | New | Nov 12, 20261 filing | Nov 12, 2026 | SEC |
| Balyasny Asset Management LLC | 13G/A | 6.60%951.8K shares | – | Aug 14, 20261 filing | Aug 14, 2026 | SEC |